MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that the Research Advisory Panel of California (the “Panel”) has approved BDSI’s two Phase III protocols for its flagship BEMATM Fentanyl product. This approval allows BDSI to continue recruitment at existing investigational sites and initiate new sites for these two protocols in the state of California.
